Yomna M Nassar
C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework.
Nassar Y, Ojara F, Pérez-Pitarch A, Geiger K, Huisinga W, Hartung N, Michelet R, Holdenrieder S, Jörger M, Kloft C. C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework. Cancers (Basel) 2023; 15
15.11.2023C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework.
15.11.2023Cancers (Basel) 2023; 15
Nassar Yomna M, Ojara Francis Williams, Pérez-Pitarch Alejandro, Geiger Kimberly, Huisinga Wilhelm, Hartung Niklas, Michelet Robin, Holdenrieder Stefan, Jörger Markus, Kloft Charlotte
A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients.
Ojara F, Henrich A, Frances N, Nassar Y, Huisinga W, Hartung N, Geiger K, Holdenrieder S, Jörger M, Kloft C. A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients. CPT Pharmacometrics Syst Pharmacol 2023; 12:1714-1725.
27.02.2023A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients.
27.02.2023CPT Pharmacometrics Syst Pharmacol 2023; 12:1714-1725
Ojara Francis Williams, Henrich Andrea, Frances Nicolas, Nassar Yomna M, Huisinga Wilhelm, Hartung Niklas, Geiger Kimberly, Holdenrieder Stefan, Jörger Markus, Kloft Charlotte